Bumped-kinase inhibitors for cryptosporidiosis therapy

Matthew A. Hulverson, Sumiti Vinayak, Ryan Choi, Deborah A. Schaefer, Alejandro Castellanos-Gonzalez, Rama S.R. Vidadala, Carrie F. Brooks, Gillian T. Herbert, Dana P. Betzer, Grant R. Whitman, Hayley N. Sparks, Samuel L.M. Arnold, Kasey L. Rivas, Lynn K. Barrett, A. Clinton White, Dustin J. Maly, Michael W. Riggs, Boris Striepen, Wesley C. Van Voorhis, Kayode K. Ojo

Research output: Research - peer-reviewArticle

  • 6 Citations

Abstract

Bumped kinase inhibitors (BKIs) of Cryptosporidium parvum calcium-dependent protein kinase 1 (CpCDPK1) are leading candidates for treatment of cryptosporidiosis-associated diarrhea. Potential cardiotoxicity related to anti–human ether-à-go-go potassium channel (hERG) activity of the first-generation anti-Cryptosporidium BKIs triggered further testing for efficacy. A luminescence assay adapted for high-throughput screening was used to measure inhibitory activities of BKIs against C. parvum in vitro. Furthermore, neonatal and interferon γ knockout mouse models of C. parvum infection identified BKIs with in vivo activity. Additional iterative experiments for optimum dosing and selecting BKIs with minimum levels of hERG activity and frequencies of other safety liabilities included those that investigated mammalian cell cytotoxicity, C. parvum proliferation inhibition in vitro, anti–human Src inhibition, hERG activity, in vivo pharmacokinetic data, and efficacy in other mouse models. Findings of this study suggest that fecal concentrations greater than parasite inhibitory concentrations correlate best with effective therapy in the mouse model of cryptosporidiosis, but a more refined model for efficacy is needed.

LanguageEnglish (US)
Pages1275-1284
Number of pages10
JournalJournal of Infectious Diseases
Volume215
Issue number8
DOIs
StatePublished - 2017

Fingerprint

Cryptosporidiosis
Phosphotransferases
Therapeutics
Cryptosporidium parvum
In Vitro Techniques
High-Throughput Screening Assays
Cryptosporidium
Potassium Channels
Luminescence
Knockout Mice
Ether
Interferon-gamma
Diarrhea
Parasites
Pharmacokinetics
Safety
Infection
Cardiotoxicity
calcium-dependent protein kinase

Keywords

  • Bumped kinase inhibitors
  • Calcium-dependent protein kinase 1
  • Cryptosporidiosis treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Hulverson, M. A., Vinayak, S., Choi, R., Schaefer, D. A., Castellanos-Gonzalez, A., Vidadala, R. S. R., ... Ojo, K. K. (2017). Bumped-kinase inhibitors for cryptosporidiosis therapy. Journal of Infectious Diseases, 215(8), 1275-1284. DOI: 10.1093/infdis/jix120

Bumped-kinase inhibitors for cryptosporidiosis therapy. / Hulverson, Matthew A.; Vinayak, Sumiti; Choi, Ryan; Schaefer, Deborah A.; Castellanos-Gonzalez, Alejandro; Vidadala, Rama S.R.; Brooks, Carrie F.; Herbert, Gillian T.; Betzer, Dana P.; Whitman, Grant R.; Sparks, Hayley N.; Arnold, Samuel L.M.; Rivas, Kasey L.; Barrett, Lynn K.; White, A. Clinton; Maly, Dustin J.; Riggs, Michael W.; Striepen, Boris; Van Voorhis, Wesley C.; Ojo, Kayode K.

In: Journal of Infectious Diseases, Vol. 215, No. 8, 2017, p. 1275-1284.

Research output: Research - peer-reviewArticle

Hulverson, MA, Vinayak, S, Choi, R, Schaefer, DA, Castellanos-Gonzalez, A, Vidadala, RSR, Brooks, CF, Herbert, GT, Betzer, DP, Whitman, GR, Sparks, HN, Arnold, SLM, Rivas, KL, Barrett, LK, White, AC, Maly, DJ, Riggs, MW, Striepen, B, Van Voorhis, WC & Ojo, KK 2017, 'Bumped-kinase inhibitors for cryptosporidiosis therapy' Journal of Infectious Diseases, vol 215, no. 8, pp. 1275-1284. DOI: 10.1093/infdis/jix120
Hulverson MA, Vinayak S, Choi R, Schaefer DA, Castellanos-Gonzalez A, Vidadala RSR et al. Bumped-kinase inhibitors for cryptosporidiosis therapy. Journal of Infectious Diseases. 2017;215(8):1275-1284. Available from, DOI: 10.1093/infdis/jix120
Hulverson, Matthew A. ; Vinayak, Sumiti ; Choi, Ryan ; Schaefer, Deborah A. ; Castellanos-Gonzalez, Alejandro ; Vidadala, Rama S.R. ; Brooks, Carrie F. ; Herbert, Gillian T. ; Betzer, Dana P. ; Whitman, Grant R. ; Sparks, Hayley N. ; Arnold, Samuel L.M. ; Rivas, Kasey L. ; Barrett, Lynn K. ; White, A. Clinton ; Maly, Dustin J. ; Riggs, Michael W. ; Striepen, Boris ; Van Voorhis, Wesley C. ; Ojo, Kayode K./ Bumped-kinase inhibitors for cryptosporidiosis therapy. In: Journal of Infectious Diseases. 2017 ; Vol. 215, No. 8. pp. 1275-1284
@article{2009accd52e4482584fa4f3844470e32,
title = "Bumped-kinase inhibitors for cryptosporidiosis therapy",
abstract = "Bumped kinase inhibitors (BKIs) of Cryptosporidium parvum calcium-dependent protein kinase 1 (CpCDPK1) are leading candidates for treatment of cryptosporidiosis-associated diarrhea. Potential cardiotoxicity related to anti–human ether-à-go-go potassium channel (hERG) activity of the first-generation anti-Cryptosporidium BKIs triggered further testing for efficacy. A luminescence assay adapted for high-throughput screening was used to measure inhibitory activities of BKIs against C. parvum in vitro. Furthermore, neonatal and interferon γ knockout mouse models of C. parvum infection identified BKIs with in vivo activity. Additional iterative experiments for optimum dosing and selecting BKIs with minimum levels of hERG activity and frequencies of other safety liabilities included those that investigated mammalian cell cytotoxicity, C. parvum proliferation inhibition in vitro, anti–human Src inhibition, hERG activity, in vivo pharmacokinetic data, and efficacy in other mouse models. Findings of this study suggest that fecal concentrations greater than parasite inhibitory concentrations correlate best with effective therapy in the mouse model of cryptosporidiosis, but a more refined model for efficacy is needed.",
keywords = "Bumped kinase inhibitors, Calcium-dependent protein kinase 1, Cryptosporidiosis treatment",
author = "Hulverson, {Matthew A.} and Sumiti Vinayak and Ryan Choi and Schaefer, {Deborah A.} and Alejandro Castellanos-Gonzalez and Vidadala, {Rama S.R.} and Brooks, {Carrie F.} and Herbert, {Gillian T.} and Betzer, {Dana P.} and Whitman, {Grant R.} and Sparks, {Hayley N.} and Arnold, {Samuel L.M.} and Rivas, {Kasey L.} and Barrett, {Lynn K.} and White, {A. Clinton} and Maly, {Dustin J.} and Riggs, {Michael W.} and Boris Striepen and {Van Voorhis}, {Wesley C.} and Ojo, {Kayode K.}",
year = "2017",
doi = "10.1093/infdis/jix120",
volume = "215",
pages = "1275--1284",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Bumped-kinase inhibitors for cryptosporidiosis therapy

AU - Hulverson,Matthew A.

AU - Vinayak,Sumiti

AU - Choi,Ryan

AU - Schaefer,Deborah A.

AU - Castellanos-Gonzalez,Alejandro

AU - Vidadala,Rama S.R.

AU - Brooks,Carrie F.

AU - Herbert,Gillian T.

AU - Betzer,Dana P.

AU - Whitman,Grant R.

AU - Sparks,Hayley N.

AU - Arnold,Samuel L.M.

AU - Rivas,Kasey L.

AU - Barrett,Lynn K.

AU - White,A. Clinton

AU - Maly,Dustin J.

AU - Riggs,Michael W.

AU - Striepen,Boris

AU - Van Voorhis,Wesley C.

AU - Ojo,Kayode K.

PY - 2017

Y1 - 2017

N2 - Bumped kinase inhibitors (BKIs) of Cryptosporidium parvum calcium-dependent protein kinase 1 (CpCDPK1) are leading candidates for treatment of cryptosporidiosis-associated diarrhea. Potential cardiotoxicity related to anti–human ether-à-go-go potassium channel (hERG) activity of the first-generation anti-Cryptosporidium BKIs triggered further testing for efficacy. A luminescence assay adapted for high-throughput screening was used to measure inhibitory activities of BKIs against C. parvum in vitro. Furthermore, neonatal and interferon γ knockout mouse models of C. parvum infection identified BKIs with in vivo activity. Additional iterative experiments for optimum dosing and selecting BKIs with minimum levels of hERG activity and frequencies of other safety liabilities included those that investigated mammalian cell cytotoxicity, C. parvum proliferation inhibition in vitro, anti–human Src inhibition, hERG activity, in vivo pharmacokinetic data, and efficacy in other mouse models. Findings of this study suggest that fecal concentrations greater than parasite inhibitory concentrations correlate best with effective therapy in the mouse model of cryptosporidiosis, but a more refined model for efficacy is needed.

AB - Bumped kinase inhibitors (BKIs) of Cryptosporidium parvum calcium-dependent protein kinase 1 (CpCDPK1) are leading candidates for treatment of cryptosporidiosis-associated diarrhea. Potential cardiotoxicity related to anti–human ether-à-go-go potassium channel (hERG) activity of the first-generation anti-Cryptosporidium BKIs triggered further testing for efficacy. A luminescence assay adapted for high-throughput screening was used to measure inhibitory activities of BKIs against C. parvum in vitro. Furthermore, neonatal and interferon γ knockout mouse models of C. parvum infection identified BKIs with in vivo activity. Additional iterative experiments for optimum dosing and selecting BKIs with minimum levels of hERG activity and frequencies of other safety liabilities included those that investigated mammalian cell cytotoxicity, C. parvum proliferation inhibition in vitro, anti–human Src inhibition, hERG activity, in vivo pharmacokinetic data, and efficacy in other mouse models. Findings of this study suggest that fecal concentrations greater than parasite inhibitory concentrations correlate best with effective therapy in the mouse model of cryptosporidiosis, but a more refined model for efficacy is needed.

KW - Bumped kinase inhibitors

KW - Calcium-dependent protein kinase 1

KW - Cryptosporidiosis treatment

UR - http://www.scopus.com/inward/record.url?scp=85024488093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024488093&partnerID=8YFLogxK

U2 - 10.1093/infdis/jix120

DO - 10.1093/infdis/jix120

M3 - Article

VL - 215

SP - 1275

EP - 1284

JO - Journal of Infectious Diseases

T2 - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 8

ER -